18 completed. 18 Phase 2, 2 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 18 |
| Phase 1 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Adrenocortical Hyperfunction: new trials by email Literature Review of Adrenocortical Hyperfunction trials Research Report on Adrenocortical Hyperfunction
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome atumelnant - Cushing Syndrome, Cushing Disease | Phase 1 / Phase 2 | Completed | Crinetics Pharmaceuticals Inc. | 19 | 2023-10-12 | 2026-10-14 |
| SPI-62 as a Treatment for Adrenocorticotropic Hormone-dependent Cushing's Syndrome SPI-62, Placebo - Cushing's Syndrome I, Cushing Disease Due to Increased ACTH Secretion | Phase 2 | Completed | Sparrow Pharmaceuticals | 26 | 2022-09-01 | 2025-10-08 |
| A Study of CIN-107 in Adults With Primary Aldosteronism CIN-107 2 mg dosing, CIN-107 4 mg dosing, CIN-107 8 mg dosing - Primary Aldosteronism, Hyperaldosteronism | Phase 2 | Completed | AstraZeneca | 15 | 2021-03-08 | 2026-03-03 |
| Calcium Channel Blockade in Primary Aldosteronism Amlodipine - Primary Aldosteronism, Primary Aldosteronism Due to Adrenal Hyperplasia (Bilateral) | Phase 2 | Completed | Brigham and Women's Hospital | 15 | 2020-09-01 | 2025-04-15 |
| 11C-Metomidate PET/CT for Endocrine Hypertension and Characterisation of Adrenal Tumours 11C-Metomidate PET/CT imaging at Clinical Imaging Research Centre - Primary Aldosteronism Due to Aldosterone Producing Adenoma, Primary Aldosteronism | Phase 2 / Phase 3 | Completed | Changi General Hospital | 97 | 2019-12-30 | 2026-10-26 |
| DP13 - A Phase II Study in Patients With Primary Aldosteronism dexfadrostat phosphate - Primary Aldosteronism | Phase 2 | Completed | Damian Pharma AG | 35 | 2019-11-21 | 2024-11-22 |
| Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699 osilodrostat - Cushing's Syndrome | Phase 2 | Completed | RECORDATI GROUP | 127 | 2018-10-05 | 2024-12-18 |
| Open-label Study on Treatment of Primary Aldosteronism With Everolimus Everolimus 0.75 mg - Primary Aldosteronism | Phase 2 | Completed | University Hospital, Basel, Switzerland | 12 | 2017-05-22 | 2019-01-09 |
| Endocrine Cardiomyopathy in Cushing Syndrome: Response to Cyclic GMP PDE5 inhibitOrs Tadalafil - Cushing's Syndrome Cardiomyopathy | Phase 2 | Completed | Andrea M. Isidori | 18 | 2016-07-01 | 2023-05-16 |
| Study to Evaluate CORT125134 in Participants With Cushing's Syndrome CORT125134 - Cushing's Syndrome | Phase 2 | Completed | Corcept Therapeutics | 35 | 2016-06-01 | 2019-10-15 |
| Study of Efficacy and Safety of Osilodrostat in Cushing's Syndrome Osilodrostat - Cushing's Syndrome, Ectopic Corticotropin Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 9 | 2015-09-24 | 2020-05-06 |
| Abiraterone With Different Steroid Regimens for Side Effect Related to Mineralcorticoid Excess Prevention in Prostate Cancer Prior to Chemotherapy Abiraterone Acetate, Prednisone 5 mg twice daily, Prednisone 5 mg once daily - Prostate Cancer | Phase 2 | Completed | Janssen Pharmaceutica N.V., Belgium | 164 | 2013-07-16 | 2019-07-05 |
| The Role of Aldosterone on Augmented Exercise Pressor Reflex in Hypertension Eplerenone, Amlodipine, Microneurography - Hypertension | Phase 2 | Completed | University of Texas Southwestern Medical Center | 14 | 2013-07-01 | 2022-03-18 |
| Mifepristone Effects on Glucose Intolerance in Obese/Overweight Adults Mifepristone, Placebo - Endocrine Disease, Diabetes | Phase 1 / Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 19 | 2011-11-29 | 2021-04-14 |
| Safety and Efficacy of LCI699 in Cushing's Disease Patients LCI699 - Cushings Disease, Cushing Disease | Phase 2 | Completed | Novartis Pharmaceuticals | 31 | 2011-03-23 | 2021-01-22 |
| Proof-of-concept for the Aldosterone Synthase Inhibitor LCI699 in Patients With Primary Hyperaldosteronism LCI699 - Primary Hyperaldosteronism | Phase 2 | Completed | Novartis | 12 | 2008-06-01 | 2009-08-26 |
| A Study to Assess SOM230 in Patients With Pituitary Cushing's Disease SOM230 s.c. - Cushing's Syndrome | Phase 2 | Completed | Novartis Pharmaceuticals | 26 | 2004-04-01 | 2016-11-07 |
| New Imaging Techniques in the Evaluation of Patients With Ectopic Cushing Syndrome Pentetreotide, 18F-DOPA, CT scan - Cushing Syndrome, Endocrine Disease | Phase 2 | Completed | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) | 95 | 1999-05-20 | 2021-04-14 |
Cushing Syndrome (9) · Hyperaldosteronism (8) · ACTH Syndrome, Ectopic (4) · Pituitary ACTH Hypersecretion (4) · Hypertension (3) · Adrenal Cortex Neoplasms (2) · Endocrine System Diseases (2) · Acth-Independent Macronodular Adrenal Hyperplasia (1) · Adrenal Gland Neoplasms (1) · Adrenocortical Carcinoma (1) · Diabetes Mellitus (1) · Diabetes Mellitus, Type 2 (1) · Glucose Intolerance (1) · Hypertrophy, Left Ventricular (1)
Adrenal Gland Diseases (18) · Endocrine System Diseases (16) · Neoplasms (6) · Brain Diseases (4) · Cardiovascular Diseases (4) · Central Nervous System Diseases (4) · Hyperpituitarism (4) · Hypothalamic Diseases (4) · Neoplasms by Site (4) · Nervous System Diseases (4) · Paraneoplastic Endocrine Syndromes (4) · Paraneoplastic Syndromes (4) · Endocrine Gland Neoplasms (3) · Metabolic Diseases (3)
Osilodrostat (4) · Amlodipine (2) · Abiraterone Acetate (1) · Dexamethasone (1) · Eplerenone (1) · Everolimus (1) · Fluorodeoxyglucose F18 (1) · Magnetic Resonance Imaging (1) · Mifepristone (1) · Prednisone (1) · Tadalafil (1) · Tomography, X-Ray Computed (1) · fluorodopa F 18 (1) · pentetreotide (1) · relacorilant (1)
Novartis Pharmaceuticals (3) · Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2) · Andrea M. Isidori (1) · AstraZeneca (1) · Brigham and Women's Hospital (1) · Changi General Hospital (1) · Corcept Therapeutics (1) · Crinetics Pharmaceuticals Inc. (1) · Damian Pharma AG (1) · Janssen Pharmaceutica N.V., Belgium (1) · Novartis (1) · RECORDATI GROUP (1) · Sparrow Pharmaceuticals (1) · University Hospital, Basel, Switzerland (1) · University of Texas Southwestern Medical Center (1)
United States (11) · Italy (5) · France (3) · Japan (3) · Belgium (2) · Bulgaria (2) · Germany (2) · Hungary (2) · Netherlands (2) · United Kingdom (2) · Argentina (1) · Austria (1) · Brazil (1) · Canada (1) · China (1)
Lynnette K Nieman, M.D. (2) · Anand Vaidya, MD (1) · Andreas G Moraitis, MD (1) · Elisa Giannetta, MD - Phd (1) · Frank Czerwiec, MD (1) · Marc Y Donath, Prof. (1) · Paolo Mulatero, Prof (1) · Wanpen Vongpatanasin, MD (1)
PMID 18957506, PMID 20837883, PMID 24107737, PMID 24423285, PMID 24482099, PMID 31246234, PMID 32923850, PMID 33507248, PMID 33794293, PMID 34335465, PMID 35058882, PMID 37490693, PMID 41052284
2015 (1), ZIADK075121 (1)